Biocon
Pharma shares to continue surging despite rich valuations; HSBC lists top stock picks
Even after pharma stocks witnessed a massive bull run in 2020 and valuations seem quite rich at this juncture, global investment bank HSBC expects the momentum to continue.
Stocks in focus today: TCS, Vodafone Idea, State Bank of India, Tata Power, Biocon
Nifty futures were trading 32.50 points up at 14,287.50 on Singaporean Exchange, suggesting a gap-up start for BSE Sensex and Nifty 50 on Friday
Stocks in focus: Wipro, PNB, HDFC Bank, Biocon, AU Small Finance Bank, ICICI Prudential Life Insurance
Nifty futures were trading 35 points or 0.25 per cent up at 14,005, suggesting a record high opening for BSE Sensex and Nifty 50 in today's session
HCL Tech’s Roshini Nadar India’s richest women in 2020; check 10 richest women on Hurun rich list
HCL Technologies’ Chairperson Roshini Nadar Malhotra topped the Kotak Wealth Hurun Wealthy Women 2020 list, with total wealth of Rs 54,850 crore
Biocon share price hits fresh record high as Itolizumab drug gets DCGI nod for COVID-19 treatment
Biocon share price touched a 52-week low of Rs 211.30 apiece in August 2019, since then the stock price has zoomed 115.33 per cent, doubling the investors' wealth in less than a year
COVID-19: कोरोना के कहर में भी कमाई कराते रहे ये शेयर, क्या आगे भी बना सकते हैं मालामाल?
कोरोना संकट में भी बीएसई 100 यानी टॉप 100 कंपनियों के कुछ शेयरों का प्रदर्शन इस साल अच्छा र
Mylan and Biocon to present phase-III trastuzumab biosimilar data at ASCO annual meeting
HERITAGE study shows comparable efficacy, safety and immunogenicity to branded trastuzumab in HER2-positive metastatic breast cancer patients
Biocon shares hit 52-week high, here is why
Biocon shares surged after global pharma major Mylan Inc, and the Indian pharma company confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms, in comparison to Roche's bra
Mylan, Biocon confirm efficacy of trastuzumab biosimilar
Global pharma major Mylan Inc, and Biocon have confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms...
Biocon to invest Rs 1,060 crores in Bengaluru plant
The facility is expected to generate at least 750 jobs immediately
Delhi HC refrains from staying single judge interim order over breast cancer drug by Biocon and Mylan
The division bench of the high court, however, said the drug-makers may continue to sell their products under the brand names
Maruti Suzuki, HCL Tech, Yes Bank among 8 stocks that trended in Thursday’s trade
Maruti Suzuki shares closed 2.94 per cent down at Rs 3748.45 after Japense yen soared almost 3 per cent against the dollar and euro as the Bank of Japan opted out of any further moves to ease policy.
Exceptional income drives Biocon Q4 net up 79 % at Rs 361 crore
Biotechnology major Biocon today reported 79 per cent jump in consolidated net profit at Rs360.9 crore for the fourth quarter ended March 31, 2016, on the back of exceptional income and robust sales.
Biocon Q4 net profit jumps 79 pc to Rs 361 cr on higher sales, exceptional income
Biotechnology firm Biocon reported a 79.1 per cent increase in its net profit at Rs 360.9 crore for the fourth quarter ended March on top of higher sales and exceptional income.
Biocon Inc recalls 5,505 bottles of Simvastatin tablets in US
Biocon Inc, part of biotechnology major Biocon, is recalling in the US 5,505 bottles of cholesterol lowering Simvastatin tablets for being sub-potent, according to the USFDA.
In a first, Biocon insulin gets Japan nod
Bio-pharma major Biocon on Monday became the first Indian company to receive regulatory approval for a biosimilar insulin in Japan.
Biocon’s Insulin Glargine receives regulatory approval in Japan
The product is ready to be launched in Q1 FY17
Biocon in co-development and commercialisation agreement with Lab PiSA
The collaboration is part of Biocon’s strategy to address the large demand for generic rh-insulin in the US
Govt paying mere ‘lip service’ to manufacturing sector: Kiran Mazumdar-Shaw
Labelling government's thrust on manufacturing sector as mere "lip service", Biocon chief Kiran Mazumdar-Shaw has said that ease of doing business in India has not improved...
Biocon receives first generic formulation approval in EU
The approval will enable the company to address $1.2 billion opportunity, starting FY17 Biocon has received European approvals for its Rosuvastatin Calcium 5 mg, 10 mg, 20 mg and 40 mg tablets, a generic equivalent of Crestor
Biocon Q3 net up 13% at Rs 103 crore
Biotechnology major Biocon has reported 13.31 per cent rise in consolidated net profit of Rs 103 crore for the third quarter ended December 31, 2015-16.
Biocon shares fall post Q3 results, Syngene International gains over 7%
Biocon's contract research arm Syngene International on Thursday reported 31.25 per cent rise in net profit to Rs 58.8 crore for the third quarter of 2015-16 financial year.
Biocon introduces therapy for treatment of Hepatitis C in India
Biocon on Thursday announced introduction of an advanced novel therapy for the treatment of Hepatitis C in India - CIMIVIR-L.
Biocon share price gains as its arm NeoBiocon partners with Novartis
Biocon share price gain as much as 1.63 per cent in the early trade after the company informed BSE that NeoBiocon, a collaboration between Biocon Ltd and BR Shetty led UAE-based Neopharma, has partnered with Novartis Middle E
Sensex, Nifty to make flat-to-cautious start on GST woes; Aurobindo Pharma, Biocon in focus today
The BSE Sensex and NSE Nifty are likely to open on a soft-to-cautious note on Thursday tracking SGX Nifty
NeoBiocon partners with Novartis
To offer Vildagliptin for diabetics in the UAE
Kiran Mazumdar Shaw led Biocon targets emerging, developed markets with biosimilars
Biopharmaceuticals firm Biocon is looking to tap opportunities in biosimilars targeting diseases such as diabetes and cancer among others, in both emerging and developed markets.
